Company intelligence / Profile preview

Titan Company

South San Francisco, California, United Statestitancompany.in ↗

Ownership: Private
Development stage: Commercial

Overview

Titan developed and commercialized Probuphine®, a buprenorphine implant for opioid use disorder. The product was approved by the FDA in May 2016 but commercialization ceased in October 2020. The company shifted focus to developing new ProNeura-based products for other chronic conditions. In August 2024 it became a wholly-owned subsidiary of BSKE Ltd.

Therapeutic areas: PsychiatryDermatologyEndocrinologyNeurology
Modalities: Small moleculeImplantable drug delivery device
Industry: Biotech

Partnerships

Braeburn Pharmaceuticals (commercialization partner for Probuphine)Molteni Farmaceutici/Merck Group subsidiary (European licensing partner)Fedson Inc. (asset sale agreement)

Beyond the preview

Go deeper on Titan Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Titan Company.

Explore the full profile